José M. Cisneros

Dr. José M. Cisneros

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
ESElena Salamanca
Elena Salamanca
MCMarina de Cueto
Marina de Cueto
PHPo-Ren Hsueh
Po-Ren Hsueh
PVPierluigi Viale
Pierluigi Viale
EJE Jové
E Jové

22 September 2008 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
JAJuan C. Alcalá
Juan C. Alcalá
JCJosé M. Cisneros
José M. Cisneros
FGFabio Grill
Fabio Grill
AOAntonio Oliver
Antonio Oliver
APAlvaro Pascual
Alvaro Pascual
Extended-spectrumβ-lactamase (ESBL)-producing Escherichia coli has emerged worldwide as a significant group of community pathogens.1,2 This is of clinical importance because E coli is the most common cause of community-acquired urinary tract infections (UTIs), and ESBL-producing isolates are frequently resistant to many of the antimicrobial agents recommended for the treatment of such infections; this is particularly true of oral agents.3 While many studies have reported the microbiological characterization of community-acquired ESBL-producing E coli, published data that are clinically orientated are scarce; the few studies published concerning risk factors or the clinical significance of such infections involved only small samples of cases and were carried out in individual centers.4-6 As the epidemiologic features of ESBL-producing organisms may show significant local variations, multicenter studies are particularly important to obtain comprehensive knowledge of risk factors for these infections. Likewise, studies that evaluate the efficacy of the few potentially useful oral drugs available for treatment are also needed.

15 June 2009 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JCJulián De La Torre Cisneros
Julián De La Torre Cisneros
ADAntonio Doblas
Antonio Doblas
JAJosé María Aguado
José María Aguado
RJRafael San Juan
Rafael San Juan
MBMarino Blanes
Marino Blanes
SDSpanish Network for Research in Infectious Diseases
Spanish Network for Research in Infectious Diseases
Background. It is necessary to clarify the incidence of and risk factors for tuberculosis (TB) among solid-organ transplant (SOT) recipients as well

1 December 2017 in The Lancet Haematology
Verified
Journal Article
Closed access
MAManuela Aguilar-Guisado
Manuela Aguilar-Guisado
IEIldefonso Espigado
Ildefonso Espigado
AMAlmudena Martín-Peña
Almudena Martín-Peña
CGCarlota Gudiol
Carlota Gudiol
CRCristina Royo-Cebrecos
Cristina Royo-Cebrecos
JCJosé M. Cisneros
José M. Cisneros

1 November 2002 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JCJosé M. Cisneros
José M. Cisneros
JBJesus Rodríguez Baño
Jesus Rodríguez Baño

1 May 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RARocio Alvarez-Marin
Rocio Alvarez-Marin
LLLuis Eduardo López-Cortés
Luis Eduardo López-Cortés
JMJosé Molina
José Molina
JCJosé M. Cisneros
José M. Cisneros
JPJerónimo Pachón
Jerónimo Pachón
The increasing number of infections produced by beta-lactam–resistant Gram-positive bacteria and the morbidity secondary to these infections make it necessary to optimize the use of vancomycin. In 2009, the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Disease Pharmacists published specific guidelines about vancomycin dosage and monitoring. However, these guidelines have not been updated in the past 6 years. This review analyzes the new available information about vancomycin published in recent years regarding pharmacokinetics and pharmacodynamics, serum concentration monitoring, and optimal vancomycin dosing in special situations (obese people, burn patients, renal replacement therapy, among others). Vancomycin efficacy is linked to a correct dosage which should aim to reach an area under the curve (AUC)/MIC ratio of ≥400; serum trough levels of 15 to 20 mg/liter are considered a surrogate marker of an AUC/MIC ratio of ≥400 for a MIC of ≤1 mg/liter. For Staphylococcus aureus strains presenting with a MIC >1 mg/liter, an alternative agent should be considered. Vancomycin doses must be adjusted according to body weight and the plasma trough levels of the drug. Nephrotoxicity has been associated with target vancomycin trough levels above 15 mg/liter. Continuous infusion is an option, especially for patients at high risk of renal impairment or unstable vancomycin clearance. In such cases, vancomycin plasma steady-state level and creatinine monitoring are strongly indicated.